3 active not recruiting, 3 completed, 1 recruiting, 1 terminated. 9 Phase 2, 2 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 9 | Active not recruiting 3, Completed 3, Recruiting 1, Terminated 1, Withdrawn 1 |
| Phase 1 | 2 | Completed 1, Withdrawn 1 |
Follow Refractory Colorectal Carcinoma: new trials by email Literature Review of Refractory Colorectal Carcinoma trials Research Report on Refractory Colorectal Carcinoma
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| CPI-613 (Devimistat) in Combination With Hydroxychloroquine and 5-fluorouracil or Gemcitabine in Treating Patients With Advanced Chemorefractory Solid Tumors Biospecimen Collection, Computed Tomography, Devimistat - Advanced Biliary Tract Carcinoma, Advanced Colorectal Carcinoma | Phase 2 | Recruiting | Northwestern University | 94 | 2023-03-08 | 2023-03-10 |
| Guadecitabine and Nivolumab in Treating Refractory Metastatic Colorectal Cancer Guadecitabine, Nivolumab - Colorectal Adenocarcinoma, CpG Island Methylator Phenotype | Phase 1 / Phase 2 | Withdrawn | University of Southern California | 2020-01-30 | 2021-04-05 | |
| TAS-102 and Oxaliplatin for the Treatment of Refractory Stage IV Colon Cancer Oxaliplatin, Trifluridine and Tipiracil Hydrochloride - Metastatic Colorectal Carcinoma, Recurrent Colon Carcinoma | Phase 2 | Active not recruiting | Rutgers, The State University of New Jersey | 50 | 2019-02-12 | 2024-11-18 |
| Circulating Cell-Free Tumor DNA Testing in Guiding Treatment for Patients With Advanced or Metastatic Colorectal Cancer Best Practice, Laboratory Procedure, Quality-of-Life Assessment - Refractory Colorectal Carcinoma, Stage III Colorectal Cancer AJCC v8 | Phase 2 | Active not recruiting | M.D. Anderson Cancer Center | 100 | 2019-01-29 | 2026-08-07 |
| Nivolumab and Metformin in Patients With Treatment Refractory MSS Colorectal Cancer Metformin, Nivolumab - Colorectal Adenocarcinoma, Metastatic Microsatellite Stable Colorectal Carcinoma | Phase 2 | Completed | Emory University | 29 | 2019-01-15 | 2024-09-05 |
| Autologous Tumor Infiltrating Lymphocytes MDA-TIL in Treating Patients With Recurrent or Refractory Ovarian Cancer, Colorectal Cancer, or Pancreatic Ductal Adenocarcinoma Autologous Tumor Infiltrating Lymphocytes MDA-TIL, Cyclophosphamide, Fludarabine - Malignant Solid Neoplasm, Metastatic Colorectal Adenocarcinoma | Phase 2 | Terminated | M.D. Anderson Cancer Center | 16 | 2018-10-16 | 2025-04-17 |
| M7824 in Patients With Metastatic Colorectal Cancer or With Advanced Solid Tumors With Microsatellite Instability Anti-PD-L1/TGFbetaRII Fusion Protein M7824 - Colon Adenocarcinoma, High-Frequency Microsatellite Instability | Phase 1 / Phase 2 | Completed | M.D. Anderson Cancer Center | 4 | 2018-03-07 | 2024-11-27 |
| Capecitabine and Bevacizumab With or Without Atezolizumab in Treating Patients With Refractory Metastatic Colorectal Cancer Atezolizumab, Bevacizumab, Capecitabine - Metastatic Colorectal Carcinoma, Recurrent Colorectal Carcinoma | Phase 2 | Completed | Academic and Community Cancer Research United | 133 | 2017-07-07 | 2024-08-23 |
| Danvatirsen and Durvalumab in Treating Patients With Advanced and Refractory Pancreatic, Non-Small Cell Lung Cancer, and Mismatch Repair Deficient Colorectal Cancer Danvatirsen, Durvalumab - Advanced Colorectal Carcinoma, Advanced Lung Non-Small Cell Carcinoma | Phase 2 | Active not recruiting | M.D. Anderson Cancer Center | 39 | 2017-03-02 | 2025-05-06 |
Colorectal Neoplasms (9) · Colonic Neoplasms (2) · Lung Neoplasms (2) · Ovarian Neoplasms (2) · Pancreatic Neoplasms (2) · Adenocarcinoma of Lung (1) · Carcinoma, Non-Small-Cell Lung (1) · Carcinoma, Transitional Cell (1) · Microsatellite Instability (1) · Neoplasm Metastasis (1) · Rectal Neoplasms (1) · Turcot syndrome (1)
Colonic Diseases (9) · Digestive System Diseases (9) · Digestive System Neoplasms (9) · Gastrointestinal Diseases (9) · Gastrointestinal Neoplasms (9) · Intestinal Diseases (9) · Intestinal Neoplasms (9) · Neoplasms (9) · Neoplasms by Site (9) · Rectal Diseases (9) · Endocrine Gland Neoplasms (3) · Endocrine System Diseases (3) · Adnexal Diseases (2) · Female Urogenital Diseases (2) · Female Urogenital Diseases and Pregnancy Complications (2)
Disulfides (2) · Immunoglobulin G (2) · Nivolumab (2) · Trifluridine (2) · trifluridine tipiracil drug combination (2) · 4-toluenesulfonyl fluoride (1) · Bevacizumab (1) · Capecitabine (1) · Clinical Laboratory Techniques (1) · Cyclophosphamide (1) · Fluorouracil (1) · Gemcitabine (1) · Hydroxychloroquine (1) · Interleukin-2 (1) · Magnetic Resonance Spectroscopy (1)
M.D. Anderson Cancer Center (4) · Academic and Community Cancer Research United (1) · Emory University (1) · Northwestern University (1) · Rutgers, The State University of New Jersey (1) · University of Southern California (1)
United States (9)
Amir A Jazaeri (1) · David S Hong (1) · Devalingam Mahalingam (1) · Heinz-Josef Lenz, MD (1) · Howard S Hochster (1) · Kanwal Raghav (1) · Niharika Mettu (1) · Olumide B. Gbolahan, MBBS, MSc (1) · Van K Morris, MD (1)
PMID 31401903, PMID 33109741, PMID 35179586, PMID 37852737, PMID 38309721, PMID 39886125
P30CA014089 (1), P30CA015083 (1), P30CA060553 (1), P30CA072720 (1), P30CA138292 (1)